cystic fibrosis

Research and Markets recently released their “Cystic Fibrosis Market in Europe 2015-2019“ report, which offers an overview of current activities involving pipeline therapeutics in the ongoing fight against cystic fibrosis. Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited disease. Its primary symptoms include breathing difficulties, elevated…

The U.S. Food and Drug Administration (FDA) has classified Kitabis Pak in its Orange Book (an FDA resource listing approved drug products with therapeutic equivalence evaluations) as a therapeutic equivalent to TOBI (tobramycin inhalation solution, USP) for cystic fibrosis (CF). The administration granted it an “AN…

Concert Pharmaceuticals Inc. recently announced that their Phase 1 clinical program for deuterium-modified ivacaftor, a potentially disease-modifying treatment to address cystic fibrosis, has been initiated. Ivacaftor is available under the name Kalydeco®. This Phase 1 trial will be a crossover assessment to compare two different proprietary deuterium-modified compounds with the goal of…

Results from a new study indicate that mapping functions can be used with Cystic Fibrosis Questionnaire datasets to assess the utility values for interventions and costs related to Cystic Fibrosis. The study was recently published in the journal Health and Quality of Life Outcomes. Cystic fibrosis…

Researchers at the Research Centre for Medical Genetics in Russia and Abbott Laboratories in Russia and Germany have recently published in the Journal of Cystic Fibrosis their results on the efficacy and safety of pancreatic therapy in infants with exocrine pancreatic insufficiency (EPI) related…

A team of researchers at Aston University are currently working on understanding how bacteria present in children with a diagnosis of Cystic Fibrosis decreases their immunity, enabling other bacteria types to infect their airways. Cystic Fibrosis (CF) is a life-threatening inherited condition that affects approximately 9,000 people in the…

One size does not fit all when it comes to cystic fibrosis patients’ symptoms, despite the commonality of a mutated gene. Some patients endure severe life-long airway infections while others are relatively unaffected by their condition. Michael Knowles, MD, professor of pulmonary and critical care medicine at the University…

N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical firm committed to developing product candidates to address cystic fibrosis (CF), recently announced that the company has changed its name to Nivalis Therapeutics, Inc. Nivalis Therapeutics’ lead product candidate is N91115, a new inhibitor of S-nitrosoglutathione reductase (GSNOR) for the treatment of CF. The company’s new name, Nivalis…

A study led by researchers at West Virginia University presented a case report of a child who was diagnosed with cystic fibrosis (CF) based on an intussusception manifestation. The study was recently published in the Journal of Pediatric Surgery Case Reports and is entitled…

Researchers at the University of Colorado School of Medicine at the Anschutz Medical Campus discovered a potential cause of liver disease in young people with cystic fibrosis. The study titled “Intestinal Lesions Are Associated with Altered Intestinal Microbiome and Are More Frequent in…